Active	Status	Sponsor type	Region	Phase	Filter
5 Active 6 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lam, David CL
MCLA-158-CL01, NCT03526835: A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors	Recruiting	1/2	567	Europe, US	MCLA-158, petosemtamab, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI	Merus N.V., Chiltern International Inc., Q2 Solutions, Oncology Therapeutic Development (OTD), 4Clinics	Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma	11/25	11/27
EXCLAIM, NCT02716116 / 2016-001271-68: A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer Presentation of data for EGFR Exon20 insertion+ metastatic 2L NSCLC at ASCO 2021 May 2021 - May 2021: Presentation of data for EGFR Exon20 insertion+ metastatic 2L NSCLC at ASCO 2021 For EGFR Exon20 insertion+ metastatic 2L NSCLC Jan 2021 - Jan 2021: For EGFR Exon20 insertion+ metastatic 2L NSCLC	Active, not recruiting	1/2	334	Europe, Japan, US, RoW	TAK-788, AP32788	Takeda	Carcinoma, Non-Small-Cell Lung	03/25	03/25
NCT05198284: Prospective Decision Impact Clinical Utility Trial of KidneyIntelX	Active, not recruiting	N/A	2000	US	KidneyIntelX	Renalytix AI, Inc.	Diabetic Kidney Disease, Chronic Kidney Diseases, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3	12/23	11/26
NCT05762731: Screening for Lung Cancer in Subjects With Family History of Lung Cancer	Recruiting	N/A	1520	RoW	Low dose CT thorax	The University of Hong Kong, The Queen Elizabeth Hospital, Kwong Wah Hospital, Hong Kong Sanatorium & Hospital	Lung Cancer	12/24	12/25
Swenson, Krystal
MCLA-158-CL01, NCT03526835: A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors	Recruiting	1/2	567	Europe, US	MCLA-158, petosemtamab, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI	Merus N.V., Chiltern International Inc., Q2 Solutions, Oncology Therapeutic Development (OTD), 4Clinics	Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma	11/25	11/27